EUCTR2012-001344-22-BE进行中（未招募）1 期
A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and reactogenicity in healthy, hepatitis B virus naive adults vaccinated with the hepatitis B surface antigen in combination with a GSK Biologicals’ Adjuvant System - EARLY-CLINRES-008
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •A male or female between, and including, 18 and 45 years of age at the time of first study product administration.
- •Written informed consent obtained from the subject.
- •Healthy subjects, in the opinion of the investigator, as established by medical history, clinical examination, and clinical laboratory assessment with no active disease that could interfere with the study endpoints, before entering into the study.
- •Body Mass Index (BMI) between 18.5 and 30 kg/m2.
- •Female subjects of non-childbearing potential may be enrolled in the study
- •-Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •-has practiced adequate contraception for 30 days prior to first study product administration , and
- •-has a negative pregnancy test on the day of placebo administration/ vaccination, and
- •-has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Known history of HBV infection.
- •Previous vaccination against hepatitis B.
- •Positive for anti-hepatitis B surface (HBs) antibodies, anti-hepatitis B core (HBc) antibodies, HBsAg, HCV antibodies and/or HIV.
- •Any previous administration of vaccine components.
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first study product administration , or planned use during the study period.
- •No significant dietary restrictions or life-threatening food allergies.
- •Regular use of non steroidal anti-inflammatory drugs within 1 month prior to first study product administration .
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first study product administration. Inhaled and topical steroids are allowed.
- •Planned administration / administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study product administration and during the entire study period(both Steps), with the exception of the influenza vaccine (pandemic or seasonal) which can be administered > 21 days preceding or > 21 days following each placebo/vaccine administration.
- •Administration of immunoglobulins and/or any blood products within the last 3 months preceding the first study product administration or planned administration during the study period.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV based on screening evaluations and on medical history and physical examination.
- •History of or current bleeding or coagulation disorder.
- •Any known or clinical signs of anaemia or any clinical condition (including vascular disorder) that would preclude frequent blood drawings.
- •Poor venous access as assessed at screening by the investigator.
- •Blood loss, including blood donation, of more than 300 mL within 90 days before the first study product administration .
- •History of or current autoimmune or other immune-mediated disease.
- •Any haematological or biochemical level out of normal range before entering into the study, as follows:
- •-Haemoglobin level < lower normal limit (LNL).
- •-Platelet counts out of normal range.
- •-Alanine aminotransferase [ALT] > upper normal limit (UNL).
- •-Aspartate aminotransferase [AST] > UNL.
- •-Creatinine > UNL.
- •-c-reactive protein [CRP] > UNL.
- •-Creatine phosphokinase [CPK] > UNL without any plausible explanation for this abnormality (such as sport activity).
- •In case of haematological and/or biochemical value out of range for parameters mentioned here above, one re-testing of out of range value may be performed.
- •Any acute or chronic, clinically significant disease, as determined by medical history, physical examination or laboratory screening tests.
- •Known or suspected reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •Acute disease and/or fever at the time of enrolment.
- •-Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
- •-Fever is defined as temperature = 37.5°C for oral route.
- •Pregnant or lactating female.
- •Recent history of chronic alcohol consumption and/or drug abuse.
- •Other conditions that the principal investigator judges may interfere with study findings.
研究者
相似试验
撤回
2 期
A phase II, double blind randomized study to evaluate the efficacy of the therapeutic HIV-1 vaccine NYVAC-B versus placebo in chronic HIV-1 infected patients successfully treated with HAART (TheraVac-03)NL-OMON31815EuroVacc Foundation15
进行中（未招募）
不适用
Clinical phase II study of the sedative remimazolam in general narcosis in adult patients undergoing heart surgery, including subsequent care in the post-anaesthesia/intensive care unit, in order to evaluate the effects, tolerability, and metabolism of remimazolamAnaesthesia in adult patients undergoing cardiac surgery.MedDRA version: 16.0Level: LLTClassification code 10021722Term: Induction and maintenance anaesthesiaSystem Organ Class: 100000004865EUCTR2013-001113-32-DEPAION UK Limited
进行中（未招募）
1 期
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatmentEUCTR2013-000762-11-DEEuropean Organisation for Research and Treatment of Cancer (EORTC)115
招募中
2 期
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatmenthigh grade uterine sarcoma (HGUtS)10038594uterine sarcomaNL-OMON53073European Organisation for Research in Treatment of Cancer (EORTC)6
进行中（未招募）
1 期
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatmentEUCTR2013-000762-11-NLEuropean Organisation for Research and Treatment of Cancer (EORTC)78